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Abstract
Here, we describe the use of a ﬂuorescence based lateral ﬂow competition assay for the screening
of four classes of drugs, viz, Δ9-tetrahydrocannabinol (THC), cocaine (through the detection of ben-
zoylecgonine, BZE), opiates (through the detection of morphine, MOR) and amphetamine (AMP)
present in the sweat of a ﬁngerprint. The Drug Screening Cartridge was speciﬁcally developed for
ﬁngerprint sample collection and analysis. For this study, the cut-offs were set at: 190, 90, 68 and
80 pg/ﬁngerprint for THC, BZE, MOR and AMP, respectively. Working with three UK coroners, the
Drug Screening Cartridge, together with its ﬂuorescence reader, was applied to the detection of
drugs in the sweat of a ﬁngerprint from deceased individuals. The study shows that there was suf-
ﬁcient sweat present on the ﬁngertips to enable analysis and that the Drug Screening Cartridge
could detect the presence, or absence, of each drug. The presence of the drugs was conﬁrmed
using LC–MS-MS analysis of a second ﬁngerprint sample collected simultaneously. Excellent cor-
relation was achieved between the results obtained from the Drug Screening Cartridge and the
LC–MS-MS analysis of the ﬁngerprint samples obtained from 75 individuals. The accuracy of the
results was: 99% for THC; 95% for BZE; 96% for MOR and 93% for AMP. The results obtained using
the Drug Screening Cartridge were also compared to toxicological analysis of blood and urine
samples with good correlation. The accuracy of the results between the Drug Screening Cartridge
and blood was: 96%, 92%, 88% and 97% for THC, BZE, MOR and AMP, respectively. The compari-
son with urine showed an accuracy ranging between 86% and 92%. This ﬁngerprint sample
method has a collection time of just 5 s and a total analysis time of <10mins. These results show
that the lateral ﬂow Drug Screening Cartridge is an excellent screening test to provide information
on drug use from the sweat in a single ﬁngerprint sample.
Introduction
Drugs of abuse taken by an individual are typically detected by mea-
surement of the analytes within urine (1), blood (2) or, more
recently, saliva (3, 4). Alternative sample matrices include hair (5)
and sweat, the latter collected using patches placed on the arm or
back of an individual (3, 6–10). With these samples, the drugs of
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abuse are typically separated from the matrix using gas or liquid
chromatography and then detected using mass spectrometry, GC–
MS or LC–MS, respectively (1, 3, 6–11). Recently, it has been
shown that drug metabolites can be detected in the sweat deposited
in a latent ﬁngerprint using antibody-nanoparticle conjugates
(12–15). Drug metabolites that have been detected using such nano-
particle conjugates include, cotinine, from tobacco users (12, 14);
benzoylecgonine from cocaine users (13, 15); morphine from heroin
users (15); and methadone and its metabolite 2-ethylidene-1,5-
dimethyl-3,3-diphenylpyrrolidine (EDDP) from patients undergoing
drug dependency treatment (13). In addition, it has been shown that
two drug metabolites, benzoylecgonine and morphine, can be
detected in a single ﬁngerprint from individuals using both cocaine
and heroin (15). Subsequently, it was reported by Jickells et al., that
methadone and EDDP could be quantiﬁed from ﬁngerprints,
obtained from patients receiving treatment for heroin dependency,
that had been dissolved and then analysed using LC–MS-MS (16).
The typical concentrations found were 0.90–9.20 and 0.07–0.08 ng
per ﬁngerprint for methadone and EDDP, respectively. The same
group were able to detect lorazepam, a drug associated with drug
facilitated sexual assault, in the ﬁngerprints of healthy volunteers
given a single 2-mg oral dose of the drug. Since the lorazepam dose
was of a low concentration, ten ﬁngerprints from each volunteer
were combined and the drug, together with its glucuronide metabo-
lite, were detected using LC–MS-MS at a concentration of 11 and
210 pg, respectively (17). Surface-assisted laser desorption/ionization
(SALDI)-MS has been used to detect illicit drugs and their metabo-
lites in exogenously doped ﬁngerprints and those obtained from
known drug users (18). Through the use of a hydrophobic silica
powder to act as a SALDI enhancer, contact residues of codeine,
diacetylmorphine (heroin), cocaine and products related to opium
resin have all been detected in ﬁngerprints (18). The SALDI–MS
technique has also been used to detect methadone/EDDP and nico-
tine/cotinine in volunteer’s ﬁngerprints (19). Desorption electrospray
ionization (DESI)–MS has been used to image ﬁngerprints through
the detection of a molecular ion associated with either endogenous
or exogenous (doped) species (20, 21). Endogenous species such as
cis-hexadec-6-enoic acid, steric acid, cis-octadec-8-enoic acid, palmi-
tic acid, pentadecyclic acid, myristic acid and triacylglycerols in
sebum-rich ﬁngerprints have all been used to image ﬁngerprints
(20). Additionally, ﬁngerprints were imaged using molecular ions
from cocaine, THC and the explosive trinitrohexahydro-1,3,5-tri-
azine (RDX) that had been used to artiﬁcially dope ﬁngers (20). In a
proof of concept study, matrix-assisted laser desorption ionization
(MALDI)–MS has been used where the endogenous compound,
oleic acid, has been used to image a ﬁngerprint (22). The techniques
have been developed so that ﬁngermarks found at crime scenes have
been assessed for the presence of cocaine and THC (23). In related
work, it has been shown that cocaine and its metabolites, benzoylec-
gonine and methylecgonine, can be detected from a single ﬁngerprint
of drug users using MALDI ion mobility tandem mass spectrometry
(MALDI–IMS–MS-MS) and DESI–MS (24). Most recently, it has
been shown that cocaine, benzoylecgonine and methylecgonine can
be identiﬁed, with limits of detection of 1, 2 and 31 ng/mL, respec-
tively, in single ﬁngerprint samples using paper spray mass spec-
trometry (25).
An indirect competition immunoassay has been reported for the
detection of cocaine in drug user samples (26). In this instance, the
assay provided a quantitative measure of the concentration of
cocaine in a ﬁngerprint sample (ca. 0.3–0.9 ng/mL cocaine in a dis-
solved ﬁngerprint). This concentration was then compared to the
concentration found in saliva samples from the same individuals.
Individuals with high concentrations of cocaine in saliva were found
to have high concentrations present in the sweat deposited in a ﬁn-
gerprint, suggesting a direct relationship of the concentration of the
cocaine in the two matrices (26). The methods used for the detection
of drugs of abuse, their metabolites and other species in ﬁngerprints
have been reviewed (27–29).
In this present study we show, for the ﬁrst time, that an innova-
tive lateral ﬂow device can enable the detection of four different
drug classes from a single ﬁngerprint sample in <10mins. Working
with three UK H.M. Coroners, the lateral ﬂow device was applied
to the detection of drugs of abuse in the sweat of a ﬁngerprint from
deceased individuals. The study shows that not only was there sufﬁ-
cient sweat present on the ﬁngertips of the deceased individual to
perform the analytical measurements but that the lateral ﬂow device
could detect the presence, or absence, of the four classes of drugs of
abuse. The presence of the drugs was conﬁrmed using LC–MS-MS
analysis of a second ﬁngerprint sample from the same individual.
Finally, these analyses are compared to analysis of other bodily ﬂuid
samples, viz., blood and urine. The results highlight that the lateral
ﬂow device can rapidly screen for drug use in individuals using a ﬁn-
gerprint sample that is easy to collect and does not generate poten-
tially toxic waste disposal problems. The study also shows that the
lateral ﬂow device can be used by coroners and their staff to assist
in understanding the possible cause of death and to inform potential
further post-mortem activities. Most importantly, this study shows
that the lateral ﬂow device can be used in a variety of situations to
readily detect drugs of abuse in the sweat of a ﬁngerprint from an
individual.
Methods
The lateral ﬂow device is a screening test that can provide informa-
tion on drug use from the analysis of the sweat from a collected ﬁn-
gerprint sample. Sweat samples were collected using a single use,
disposable plastic Drug Screening Cartridge (Intelligent
Fingerprinting Drug Screening Cartridge DOA114, Cambridge, UK;
Figure 1).
Figure 1. (A) Schematic diagram and (B) image showing the ﬁngerprint Drug
Screening Cartridge.
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Sample collection and ethics
Each ﬁngerprint sweat sample was collected by a mortuary staff
member by pressing, using ﬁrm pressure, a ﬁngertip of an individual
onto the sample collection area of the cartridge for a period of 5 s.
This time period enables transfer of the sweat from the ﬁngertip onto
the test collection area. The anti-tamper cover was used to protect
the sample from contamination or adulteration. The Drug Screening
Cartridges were conﬁgured to detect four drug classes: Δ9-tetrahy-
drocannabinol, cocaine (through detection of benzoylecgonine), opi-
ates (through the detection of morphine), and amphetamine from a
single ﬁngerprint sample. Once collected, the sample was then ana-
lysed for information concerning drug use by ﬂuorescence analysis
using the Intelligent Fingerprinting Reader 1000 unit (IFR001;
Intelligent Fingerprinting Ltd., Cambridge, UK) (Figure 2). A poten-
tial concern when detecting drugs in the sweat of a ﬁngerprint is that
the person may have handled or accidentally come into contact with
a trace residue of a particular drug. When live subjects are tested,
simply washing the hands with soap and water and drying them with
paper towel removes trace residues. Sufﬁcient sweat then appears
after 10–15min to obtain a sweat sample, which is not adulterated
with contact residues, that can be used to detect whether the person
has used one, or more, of the four drug classes. Obviously the hand-
washing strategy is not possible with deceased individuals. By detect-
ing the drug metabolite rather than the parent molecule partially
overcomes the issue of a trace residue within the ﬁngerprint sweat.
Consequently, the metabolites of cocaine and heroin, BZE and mor-
phine respectively, were detected. For THC and amphetamines the
parent molecule was detected so accidental contact with these drugs
prior to death may give a positive result. In all instances, the detection
of the presence of drugs in the ﬁngerprint sweat should be used as a
screen, with all positive results conﬁrmed using LC–MS-MS.
The process for analysis of the collected ﬁngerprint sweat sample
is as follows. The Drug Screening Cartridge activation buffer clip is
depressed (see Figure 1)—this releases buffer solution into the sam-
ple collection cartridge. The sample collection cartridge is then
inserted into the Reader 1000 analysis tray, as shown in Figure 2,
and after following instructions, as directed by the Reader 1000
touch-screen, the results of the analysis of the test are displayed on
the screen within 8min of initiating the test. The result of each test
gives a pass/fail for the presence of each drug, based on a cut-off for
each analyte. For this study, the cut-offs for each drug detected using
the lateral ﬂow device were set at 190 pg for THC, 90 pg for BZE,
68 pg for morphine and 80 pg for amphetamine. The results
obtained using the Drug Screening Cartridge and Reader 1000 can
be printed to provide a permanent record.
Fingerprint sweat samples were collected from three UK coroner
areas involved in the study: Plymouth, Torbay & South Devon;
South Yorkshire (West) and Staffordshire (South). Under the appro-
priate consented jurisdiction of each coroner, ﬁngerprint sweat sam-
ples were collected by mortuary staff from routine mortuary case
submissions. Mortuary staff were asked not to preselect cases to
ensure a wide cross-section of individuals. The collected samples
and all test results were anonymised, and a full chain of evidence
continuity was maintained during sample collection and analysis.
The time since death and sample collection varied between cases.
Each sample was analysed for the following drug groups: canna-
bis; cocaine; opiates and amphetamines. A total of three sets of
analyte data were collected from each individual: (1) results of
screening tests carried out within the mortuary, by mortuary staff,
using the ﬁngerprint Drug Screening Cartridge (in situ tests); (2)
results of quantitative tests carried out by an independent third-
party analytical laboratory on ﬁngerprint samples collected in
parallel with the screening tests—the conﬁrmatory ﬁngerprint was
collected on a Collection Cartridge (Intelligent Fingerprinting
DOA150, Cambridge UK) which was speciﬁcally designed for ease
of analysis of a ﬁngerprint using LC–MS-MS; (3) Results of quanti-
tative tests carried out as part of post-mortem examination toxicol-
ogy tests. The results of these three sets of data were used to assess
the accuracy of the ﬁngerprint Drug Screening Cartridge and reader.
Conﬁrmatory analysis
As stated above, for conﬁrmatory analysis of the presence of drugs
in a ﬁngerprint, a second ﬁngerprint was collected from each indi-
vidual. The second, conﬁrmatory, ﬁngerprint was collected on a
Collection Cartridge by mortuary staff. This sample was then sealed
and sent to an independent laboratory (LGC Ltd, Fordham, UK) for
analysis. The conﬁrmation analysis of the drugs present in the ﬁn-
gerprint samples was performed using a UHPLC–MS-MS system
consisting of a Xevo-TQS mass spectrometer and Acquity I-class
UPLC system, both from Waters Ltd (Elstree, UK). Mass spectral
analysis was performed in positive electrospray mode (ESI) with
analysis performed in multiple reaction monitoring mode (MRM)
with a minimum of two MRM transitions selected for each
analyte(s).
Results and Discussion
The lateral ﬂow device is a ﬂuorescence based competition assay.
The device has four drug–bovine serum albumin (BSA) conjugate
lines drawn on the nitrocellulose test strip together with a ﬁfth line
that acts as a control test to ensure the assay is functioning correctly.
Fluorescently-tagged antibodies speciﬁc to each drug class are passed
over the four drug-conjugate lines and the control (horse anti-mouse
antibody, HAM). Upon binding to the four drug, plus the control,
conjugate lines the ﬂuorescently-tagged antibodies provide a ﬂuores-
cent signal measured by the reader. A sample with no drug present
gives a maximum ﬂuorescence signal as the ﬂuorescently-tagged
antibody readily binds to the drug-conjugate line. If a drug is present
in the sample, the drug will preferentially bind to the ﬂuorescently-
tagged antibody thereby preventing the antibody from binding to
the drug-conjugate line. This results in a decrease in the ﬂuorescence
signal. Therefore, samples with a drug present will have a decreasing
ﬂuorescence signal with increasing concentration of the analyte. To
assess the usability of the lateral ﬂow device for the detection of the
four classes of drugs, spiked solutions in 10 μl phosphate buffer
Figure 2. The Intelligent Fingerprinting Reader 1000 Unit and the Drug
Screening Cartridge.
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solution (either individual drugs or combined) were used to chal-
lenge the lateral ﬂow cartridge. Upon addition of the spiked solu-
tion, the test was activated, allowed to run for 8 min and then the
cartridge was read using the ﬂuorescence based reader. The results
of these challenge experiments are shown in Figure 3. With each
lateral ﬂow cartridge, there are ﬁve peaks associated with the con-
trol (HAM), cannabis (THC), cocaine (BZE), opiates (MOR) and
amphetamines (AMP), respectively (Figure 3a)—the respective
peaks are at positions 14.8, 18.7, 22.3, 26.0 and 29.9mm along
the length of the lateral ﬂow device. For this study, the cut-offs for
each drug to be detected using the lateral ﬂow device were set at
190 pg for THC, 90 pg for BZE, 68 pg for morphine and 80 pg for
amphetamine. The cut-offs were determined by analysing the sweat
of ﬁngerprints from a total of 2,459 volunteers who were attending
treatment programs at drug dependency clinics. Comparison of the
data from the Drug Screening Cartridge and that from a conﬁrma-
tion ﬁngerprint Collection cartridge analysed by LC–MS-MS deter-
mined the maximum efﬁciency to select the best assay
performance. Upon applying a spiked sample to a cartridge, the
respective peak decreases in ﬂuorescence intensity. When a 240-pg
THC spike was added to the phosphate buffer solution, the peak
due to the THC conjugate at 18.8mm decreased in intensity
(Figure 3b). Similar decreases of speciﬁc peak intensity were
observed when spiked samples of 90 pg benzoylecgonine, 70 pg of
morphine and 190 pg of amphetamine were applied to separate
cartridges—Figure 3C, D and E, respectively. When a buffer sam-
ple that contained all four drug spikes was applied to a cartridge,
the ﬂuorescence intensity of all four drug-conjugate lines was
decreased. In all instances, the control HAM conjugate line
remained at a constant ﬂuorescence intensity. These results show that
the lateral ﬂow Drug Screening Cartridge can detect the presence of
individual drugs, or all four drugs, present in a single sample.
Considerable studies were undertaken to investigate the cross-
reactivity of the antibodies used within the Drug Screening Cartridge.
A total of 50 drug-related compounds were assessed for potential
cross-reactivity with the four drug targets, while a further 44 com-
pounds/materials that could potentially be found on ﬁngers were
assessed as possible interferences. The speciﬁcity value of > 94%
that was obtained for all four drug classes with the mortuary screen-
ing tests (Table I, see below) highlights that the Drug Screening
Cartridge is speciﬁc for all four drug classes.
Mortuary screening tests
The lateral ﬂow screening device and reader were used to determine
whether drugs of abuse were present, and could be detected, in the
sweat that remained on the ﬁngers of deceased individuals. For this
study, the cut-offs for each drug in the ﬁngerprint sweat detected
using the lateral ﬂow device were set at 190 pg for THC, 90 pg for
BZE, 68 pg for morphine, and 80 pg for amphetamine. The tests
were performed by mortuary staff who collected a ﬁngerprint on a
Drug Screening Cartridge (Intelligent Fingerprinting DOA114) from
an individual and then a second ﬁngerprint on a Collection
Cartridge (Intelligent Fingerprinting DOA150), the latter being sent
to an independent laboratory for conﬁrmatory analysis using LC–
MS-MS. Toxicology results were also obtained by the respective
mortuary from each individual based on blood and urine samples.
The results of the mortuary screening tests carried out with the ﬁn-
gerprint Drug Screening Cartridge in comparison with the results
obtained using the LC–MS-MS analysis are summarized in Table I.
In all instances, the LC–MS-MS results were assumed to be the cor-
rect result.
The equations used to calculate the analytical characterization
data are (30):
Accuracy % TN TP / TN TP FN FP 100( ) = (( + ) ( + + + )) ×
Sensitivity % TP/ TP FN 100( ) = ( ( + )) ×
Specificity % TN/ TN FP 100( ) = ( ( + )) ×
Positive predictive value % TP/ TP FP 100( ) = ( ( + )) ×
Negative predictive value % TN/ TN FN 100( ) = ( ( + )) ×
Table I shows a summary of the analytical characterization data
for the detection of the four classes of drugs using the lateral ﬂow
screening tests performed in the mortuary with the Drug Screening
Cartridge in comparison to the results obtained from quantitative
measurements of a second ﬁngerprint, taken at the same time, that
had been solubilised and then analyzed using LC–MS-MS. Samples
from 75 individuals were collected by mortuary staff. In all cases,
there was sufﬁcient sweat on the ﬁngers for staff to obtain a ﬁnger-
print and for a full analysis to be performed, using either the lateral
ﬂow device or the LC–MS-MS measurement. The subjects were cho-
sen, at random, from routine mortuary case submissions. There was
no pre-selection to bias the study towards individuals suspected to
have died of an overdose. Therefore, it is not surprising that there
are not a large number of positive samples. Opiates are the class of
drug with the highest positive number of cases, i.e., 20. This is per-
haps to be expected as morphine is invariably used for the palliative
care of patients. The lateral ﬂow Drug Screening Cartridge was able
to successfully identify 19 of the 20 samples where opiates were
found to be present in the sweat of a ﬁngerprint. Nine individuals
were found to have cocaine present in their ﬁngerprint sweat using
the lateral ﬂow device, with only one false negative. THC and AMP
were present in only limited numbers of samples (1 and 3, respec-
tively) taken in this study.
For all four classes of drugs, the accuracy of the lateral ﬂow
Drug Screening Cartridge in comparison with the LC–MS-MS anal-
ysis gave high percentage values. The accuracy for THC, BZE,
MOR and AMP was 98.7%, 94.7%, 96.0% and 93.3%, respec-
tively, at the cut-offs of 190 pg/ﬁngerprint for THC, 90 pg/ﬁnger-
print for BZE, 68 pg/ﬁngerprint for morphine and 80 pg/ﬁngerprint
for amphetamine.
While the Drug Screening Cartridge gave an accuracy value of
>93% for all four classes of drugs from the 75 individuals tested,
there were some false negative results (THC, 0; cocaine, 1; opiates,
1; and amphetamines, 1) and some false positive results (THC, 1;
cocaine, 3; opiates, 2; and amphetamines, 4). Lateral ﬂow measure-
ments are known not to be 100% accurate and therefore such mea-
surements should only be used as a screen with LC–MS-MS
conﬁrmation of drug usage. The accuracy values obtained for the
Drug Screening Cartridge do, however, compare favorably with the
accuracy values obtained using lateral ﬂow oral ﬂuid based pro-
ducts. For example, the Cozart DDSTM device was reported to
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exhibit an accuracy that was either 80.0 or 89.9%, dependent on
the cut-off used of either 30 or 10 ng/mL, respectively, for the detec-
tion of BZE in oral ﬂuid samples (4).
The speciﬁcity of the lateral ﬂow device gave values in excess of
94% for THC, cocaine, opiates and amphetamines showing that the
Drug Screening Cartridge is speciﬁc for all four drug classes. The
Figure 3. Fluorescence intensity proﬁles for the four drug panel lateral ﬂow assay: Peaks due to the control (HAM), THC, BZE, MOR and AMP are at 14.8, 18.7,
22.3, 26 and 29.8mm, respectively. (A) No spike, just buffer only, (B) 240 pg THC spike, (C) 90 pg BZE spike, (D) 70 pg MOR spike, (E) 190 pg AMP spike and (F) A
combined spike showing signal decrease of all four peaks associated with the four drugs.
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lateral ﬂow device gave sensitivity values for THC (100%), BZE
(90%) and opiates (95%). The sensitivity of AMP was less high,
with a value of 66.7%. This lower value is likely due to the small
number of true positive samples obtained for this drug. Similarly,
the positive predictive value (PPV) results obtained were directly
dependent on the numbers of positive samples analyzed. For the opi-
ates, where 19 samples gave a true positive result, the PPV value
was 90.5%. However, the PPV decreased for cocaine (75%), THC
(50%), through to AMP (33.3%) as the numbers of true positive
samples decreased (9, 1 and 2, respectively). Presumably, a larger
number of positive samples for THC, BZE and AMP would provide
a more accurate PPV. With large numbers of negative samples for
each drug class, the negative predictive values (NPV) were high in
each instance: THC (100.0%); cocaine (98.4%); opiates (98.1%)
and AMP (98.6%).
The data in Table I clearly shows that the lateral ﬂow Drug
Screening Cartridge can be successfully used to detect drugs of abuse
from the sweat on the ﬁngers of deceased individuals with a strong
correlation to the results obtained using LC–MS-MS analysis.
Comparison to toxicology results
The results of the mortuary screening tests performed by mortuary
staff with the Drug Screening Cartridge and the ﬂuorescence based
reader as compared to the laboratory toxicology (blood) results are
summarized in Table II. It should be noted that the sample numbers
are variable as not all cases were submitted for blood toxicology.
Table II shows that the accuracy of the ﬁngerprint screening analysis
as compared to laboratory toxicological data gives high values for
all four classes of drugs. The accuracy values were: THC (96.1%);
cocaine measured as BZE (92.2%); opiates measured as MOR
(88.2%) and AMP (97.3%). The results show that the Drug
Screening Cartridge analyses were comparable to those obtained by
toxicological analysis. These results suggest that the pharmacoki-
netic excretion proﬁles of drugs and their metabolites in the sweat
present on the ﬁngertips may be similar to that in blood. A full phar-
macokinetic study would be required to conﬁrm this suggestion.
However, the accuracy values shown in Table II do suggest that
there is a good correlation between the data obtained with the Drug
Screening Cartridge and those obtained with the blood toxicology.
The comparison of the results obtained using the Drug Screening
Cartridge versus those of the blood toxicology gave an accuracy of
>88% for all four drug classes. There were some false negative (FN)
and false positive (FP) results: FN results (THC, 0; cocaine, 1; opi-
ates, 1; and amphetamines, 1) and FP results (THC, 1; cocaine, 3;
opiates, 2; and amphetamines, 4). The difference of the accuracy
obtained with the Drug Screening Cartridge and the LC–MS-MS
analysis of the second ﬁngerprint versus the comparison with blood
toxicology may be due to the drug excretion pathway differences
between ﬁngerprint sweat and blood. The speciﬁcity of the Drug
Screening Cartridge gave values of: THC (96.1%); cocaine (91.7%);
opiates (92.3%); and AMP (97.3%). For the sensitivity measure-
ments, there were not many true positive samples—so the sensitivity
of both THC and AMP could not be measured. The sensitivity for
cocaine and opiates was 100% and 75%, respectively. Similarly, the
PPV results of THC and AMP were affected by the absence of true
positive samples. The PPV results of cocaine and opiates were
42.9% and 75%, respectively. The NPV results were good with val-
ues above 92% for all four classes of drugs.
As a further examination of the performance of the lateral ﬂow
device, a comparison was made of the analytical results obtained
using the Drug Screening Cartridge with the toxicological data from
urine samples. The results are shown in Table III. Fewer samples
were submitted for urine toxicology analysis, for example, there
were no samples analyzed for THC. However, while there are fewer
samples, the analytical data, as shown in Table III, for the compari-
son of the Drug Screening Cartridge with the urine toxicological
analysis are favorable. While the correlation of the results between
Table I. Results of the mortuary screening tests using the Drug
Screening Cartridge as compared to the independent laboratory
LC–MS-MS detection of drugs in ﬁngerprint samples. Results
were obtained by collecting pairs of ﬁngerprints in parallel
Result THC Cocaine Opiates AMP
True Negative (TN) 73 62 53 68
True Positive (TP) 1 9 19 2
False Negative (FN) 0 1 1 1
False Positive (FP) 1 3 2 4
Number of Samples 75 75 75 75
Accuracy (%) 98.7 94.7 96.0 93.3
Sensitivity (%) 100.0 90.0 95.0 66.7
Speciﬁcity (%) 98.6 95.4 96.4 94.4
PPV (%) 50.0 75.0 90.5 33.3
NPV (%) 100.0 98.4 98.1 98.6
Table II. Results of the in situ mortuary drug screening tests as
compared to laboratory-based toxicology blood analysis
Result THC Cocaine Opiates AMP
True Negative (TN) 49 44 36 36
True Positive (TP) 0 3 9 0
False Negative (FN) 0 0 3 0
False Positive (FP) 2 4 3 1
Number of Samples 51 51 51 37
Accuracy (%) 96.1 92.2 88.2 97.3
Sensitivity (%) 100.0 75.0
Speciﬁcity (%) 96.1 91.7 92.3 97.3
PPV 42.9 75.0
NPV 100.0 100.0 92.3 100.0
Note: The number of samples are variable as not all cases were submitted
for (blood) toxicology analysis.
Table III. Results of the in situ mortuary drug screening tests as
compared to laboratory-based toxicology urine analysis
Result THC Cocaine Opiates AMP
True Negative (TN) 29 24 24
True Positive (TP) 4 7 0
False Negative (FN) 0 3 1
False Positive (FP) 3 2 1
Number of Samples 0 36 36 26
Accuracy (%) 91.7 86.1 92.3
Sensitivity (%) 100.0 70.0
Speciﬁcity (%) 90.6 92.3 96.0
PPV 57.1 77.8
NPV 100.0 88.9 96.0
Note: The sample numbers are variable as not all cases were submitted for
(urine) toxicology analysis.
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the Drug Screening Cartridge and the blood toxicology is particu-
larly strong, the comparison between the cartridge and the urine
toxicology is also good for accuracy, sensitivity and speciﬁcity. It
would be expected that the pharmacokinetic excretion proﬁles of
the four classes of drugs in urine and ﬁngerprint sweat matrices
would be different. The pharmacokinetic differences between sweat
and urine excretion may account for the false negative and false pos-
itive results observed in Table III. A full pharmacokinetic compari-
son of these four classes of drugs in ﬁngerprint sweat in comparison
to other matrices such as blood, urine and oral ﬂuid should be per-
formed to establish their excretion proﬁle. However, our results
show that there is a particularly strong correlation between the
Drug Screening Cartridge and blood toxicology with a reasonable
correlation with the data obtained using the cartridge in comparison
with urine toxicology.
Conclusions
In this study we have shown that a ﬂuorescence based lateral ﬂow
Drug Screening Cartridge can detect four different drug classes
(THC, cocaine, opiates and amphetamines) from a single ﬁngerprint
sample. Working with three UK coroners, the Drug Screening
Cartridge, together with its ﬂuorescence reader, was applied to the
detection of the four drug types in the sweat of a ﬁngerprint sample
taken, by mortuary staff, from deceased individuals. The study
shows that not only was there sufﬁcient sweat present on the ﬁnger-
tips of deceased individuals to enable analysis but that the lateral
ﬂow device could detect the presence, or absence, of all four classes
of drugs within a single ﬁngerprint. The presence of the drugs was
conﬁrmed using LC–MS-MS analysis of a second ﬁngerprint sample
taken at the same time. Excellent correlation, in terms of accuracy,
sensitivity and selectivity, was achieved between the results obtained
from the Drug Screening Cartridge and the LC–MS-MS analysis of
the ﬁngerprint samples obtained from 75 deceased individuals. The
accuracy of the results ranged from 93 to 99% for the four drug
classes. The results obtained using the Drug Screening Cartridge
analyses have been also compared to toxicological analysis of blood
and urine samples. Good correlation of results was obtained using
the Drug Screening Cartridge and the laboratory-based toxicology
data for both blood and urine samples. The accuracy of the results
between the lateral ﬂow Drug Screening Cartridge and blood ranged
from 88 to 97%, while the comparison for urine showed an accu-
racy of 86–92%, suggesting that there is a stronger correlation
between the results obtained using the lateral ﬂow cartridge of the
ﬁngerprint sweat and the blood toxicology. The differences between
the two sample matrices is likely to reﬂect the differing pharmacoki-
netic excretion proﬁles of the four classes of drugs.
Overall, the results highlight that the lateral ﬂow Drug Screening
Cartridge can rapidly screen for drug use in individuals using a ﬁn-
gerprint sample that is easy to collect, with a sample collection time
of just 5 s and a total analysis time of less than 10min. The study
shows that the lateral ﬂow device can be used by coroners and their
staff to assist in understanding the possible cause of death and to
inform potential further post-mortem activities. However, with con-
sideration of the wider impact of this research, this study shows that
the lateral ﬂow Drug Collection Cartridge can be used to readily
detect drug usage by individuals through direct measurement from
the sweat of a single ﬁngerprint. The utility of this work is
highlighted by the current use of Drug Screening Cartridge and
reader in Coroner’s mortuaries, in drug rehabilitation centers, work
place testing and within high schools. Additionally, proof of concept
studies are currently being performed for airport screening and
within offender management in prisons and probation services.
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